COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00256282
Recruitment Status : Completed
First Posted : November 21, 2005
Results First Posted : May 3, 2018
Last Update Posted : May 3, 2018
Information provided by (Responsible Party):
John P. Fruehauf, University of California, Irvine

Brief Summary:
This is a Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in subjects who have metastatic melanoma which has advanced beyond the point at which local therapies such as surgery or radiation therapy would be helpful. Without effective treatment, metastatic melanoma is usually a severe and fatal disease. Chemotherapy agents or combinations of chemotherapy agents have produced tumor shrinkage in some patients, which has occasionally persisted. This research involves treatment with a combination of chemotherapy drugs known to be active against melanoma alone. The investigational purpose of this study is to determine if the combination of docetaxel, vinorelbine and sargramostim will produce a response (complete or partial) in metastasis melanoma. The researchers also wants to find out what side effects are associated with this combination of drugs.

Condition or disease Intervention/treatment Phase
Metastatic Melanoma Drug: Vinorelbine Drug: Docetaxel Drug: Sargramostim Phase 2

Detailed Description:

Annually in the U.S. there is an estimated 40,000 new cases of malignant melanoma and 7000 deaths. This disease is becoming more common with its incidence increasing at a more rapid rate in the past decade than that of any other cancer except lung cancer in women. Metastatic disease responds poorly to the usual treatments with only 2 out of 30 drugs tested, DTIC and nitrosoureas, showing response rates greater than 10%. Complete responses are rare.

Metastatic melanoma is a disease with few therapeutic options. Multi-agent chemotherapy with cisplatin (CDDP), Dacarbazine (DTIC), Carmustine (BCNU), with or without Tamoxifen, offers a 20% response rate but has failed to consistently demonstrate a significant improvement in overall survival (OS) or disease-free survival (DFS) when compared to a single agent DTIC.

Recently, investigators, in an effort to combine the activity of biologic response modifiers with chemotherapy, have developed combination biochemotherapy for metastatic melanoma. Legha et al reported an overall objective response rate of 64% with a 5-day biochemotherapy regimen. O'Day et al reported similar results (overall response rate of 57%) using a modified 5-day biochemotherapy regimen.

The above regimens all have significant toxicities and modest response rates. Clearly, more effective less toxic regimens are needed.

Vinorelbine tartrate (Navelbine) and Docetaxel (Taxotere) have both shown activity against melanoma. Additionally, the combination of both drugs has shown enhanced activity against melanoma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in Patients With Metastatic Malignant Melanoma
Study Start Date : April 2003
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Arm Intervention/treatment
Experimental: Docetaxel & Vinorelbine + Sargramostim
Docetaxel, Vinorelbine, and Sargramostim
Drug: Vinorelbine
30 mg/m2 IV over 6-10 min every 14 days
Other Names:
  • Navelbine
  • NSC-608210

Drug: Docetaxel
40mg/m2 IV over 1 hour every 14 days
Other Names:
  • Taxotere
  • RP56976
  • NSC-628503

Drug: Sargramostim
250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
Other Names:
  • Recombinant GM-CSF
  • Leukine
  • Immunex
  • NSC-613795

Primary Outcome Measures :
  1. Progression-free Survival (PFS) in Patients With AJCC Stage IV Metastatic Melanoma Treated With Docetaxel and Vinorelbine as First-line or Post-first Line (Salvage) Systemic Therapy [ Time Frame: Six months from initial treatment ]
    The primary endpoint is to evaluate the six-month progression-free survival (PFS) in patients with AJCC stage IV metastatic melanoma treated with docetaxel and vinorelbine as first-line or post-first line (salvage) systemic therapy. Progressive disease is defined as any new lesion or a greater than or equal to 20% increase in the largest perpendicular diameter of the sum of the T-lesions identified on contrast enhanced CT or MRI scan.

Secondary Outcome Measures :
  1. Percentage of Patients Alive at One Year [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age greater than or equal to 18
  • Karnofsky Performance Status (KFS) of greater than or equal to 70
  • Laboratory values (performed in 14 days, inclusive prior to study drug administration):

    • Absolute neutrophil count (ANC) >1500/mm3
    • Platelet count >100,000/mm3
    • Hemoglobin > 10 g/dl
    • Blood urea nitrogen (BUN) and serum creatinine < 0.5 times the upper limit of laboratory normal
    • Total and direct bilirubin < 1.5 times the upper limit of laboratory normal
    • Serum glutamic-oxaloacetic transaminase (SGOT) and Serum glutamic pyruvic transaminase(SGPT) < 3 times the upper limit of laboratory normal
    • Alkaline phosphatase < 3 times upper limit of laboratory normal
  • Life expectancy of greater than 12 weeks
  • Written informed consent

Exclusion Criteria:

  • No recovery from all active toxicities of prior therapies
  • Surgery within 1 week prior to study drug administration, providing acute surgical toxicity is resolved
  • Subjects within acute infection treated with intravenous antibiotics
  • Frequent vomiting or medical condition that could interfere with oral medication intake (e.g., partial bowel obstruction)
  • Concurrent malignancies at other sites with the exception of surgically cured carcinoma in situ (CIS ) of the cervix, basal or squamous cell carcinoma of the skin, and prior malignancies which have not required anit-tumor treatment within the preceding 24 months
  • Known HIV-positivity or AIDS-related illness
  • Women of childbearing potential who are not using an effective method of contraception (eligible patients must have a negative urine pregnancy test 24 hours prior to administration of study drug and be practicing medically approved contraceptive precautions)
  • Men who do not use an effective method of contraception.
  • Chemotherapy within four weeks prior to study drug administration or biologic therapy/immunotherapy within two weeks prior to study drug administration
  • Completion of radiation therapy, interstitial brachytherapy, or radiosurgery within 4 weeks prior to study drug administration (patients with brain metastases from melanoma must have completed radiotherapy to the brain at least 3 weeks before study commences)
  • Bone metastases as sole reason for Stage IV disease
  • Karnofsky Performance Status of less than or equal to 60

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00256282

Layout table for location information
United States, California
Chao Family Comprehensive Cancer Center
Orange, California, United States, 92868
Sponsors and Collaborators
John P. Fruehauf
Layout table for investigator information
Principal Investigator: John P. Fruehauf, MD, PhD Chao Family Comprehensive Cancer Center
Layout table for additonal information
Responsible Party: John P. Fruehauf, Professor of Clinical Medicine, University of California, Irvine Identifier: NCT00256282    
Other Study ID Numbers: UCI 02-23
2002-2763 ( Other Identifier: University of California, Irvine )
NCI-2010-00217 ( Other Identifier: NCI Clinical Trials Reporting Program (CTRP) )
First Posted: November 21, 2005    Key Record Dates
Results First Posted: May 3, 2018
Last Update Posted: May 3, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by John P. Fruehauf, University of California, Irvine:
Metastatic Melanoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Phytogenic
Immunologic Factors
Physiological Effects of Drugs